Clinical Scorecard: Refining Animal Research: Using ‘Omics Technologies to Connect NAMs with More Informative Regulatory Studies
At a Glance
Category
Detail
Condition
Regulatory chemical, pharmaceutical, and plant-protection-product safety assessment
Key Mechanisms
Tiered integration of in silico and in vitro evidence with targeted in vivo studies that add toxicokinetic and omics data to conventional toxicology endpoints.
Target Population
Chemicals, pharmaceuticals, and plant protection products undergoing hazard or risk assessment; no patient population is specified.
Care Setting
Regulatory toxicology and safety assessment, including OECD test-guideline and NAM development contexts.
Key Highlights
NAMs have advanced in silico and in vitro hazard identification, but validation has not kept pace with method development.
The article describes targeted, information-rich in vivo studies for cases where preceding evidence is insufficient, including for potential multi-organ effects.
These studies may combine conventional endpoints with toxicokinetic measurements, metabolomics, transcriptomics in selected target organs, and other omics technologies.
Technical Guideline Plus studies are described as guideline-conformant studies that add mechanistic data.
Guideline-Based Recommendations
Diagnosis
Use chemical structure and other properties in in silico tools to help identify probable biological targets, pathways, and toxicological concerns.
Interpret available evidence in a tiered framework; the article notes that current NAMs alone may be insufficient to demonstrate absence of hazard or risk, particularly for multi-organ effects.
Management
When preceding in silico and in vitro evidence is insufficient, the described ECETOC approach uses targeted, improved in vivo studies focused on relevant toxicological modes of action.
Add mechanistic measurements, such as toxicokinetics and selected omics technologies, alongside conventional toxicological endpoints where appropriate.
TG+ studies are described as following a test guideline while providing additional mechanistic data.
Monitoring & Follow-up
Assess NAM validation elements including reproducibility, sensitivity, and specificity for regulatory decision-making.
The article describes collecting organ weights, pathology, and histopathology alongside toxicokinetic and omics measurements in information-rich studies.
Risks
The article identifies a concern that human-relevant approaches may provide insufficient protection of human health, particularly for repeated-dose endpoints.
It notes that current NAMs may not adequately demonstrate absence of risk or hazard for effects involving multiple organs.
Regulatory acceptance may be constrained by validation gaps, data interpretation and integration demands, and regulations that specify animal tests.
Patient & Prescribing Data
Not applicable; the article concerns regulatory toxicology methods and does not describe patients.
No treatment or prescribing information is provided.
